Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Pemetrexed + Anlotinib in T790M+ NSCLC Post-Osimertinib
NCT04316351Phase 2Unknown
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Apr 2020
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoint: Overall Response Rate at 2 years. Status: unknown.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04316351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04316351.